Vaccinex Stock Forecast, Price & News

+0.03 (+1.14 %)
(As of 06/14/2021 10:13 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume601 shs
Average Volume3.36 million shs
Market Capitalization$75.96 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VCNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Vaccinex logo

About Vaccinex

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

532nd out of 2,099 stocks

Pharmaceutical Preparations Industry

259th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vaccinex (NASDAQ:VCNX) Frequently Asked Questions

Is Vaccinex a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaccinex stock.
View analyst ratings for Vaccinex
or view top-rated stocks.

What stocks does MarketBeat like better than Vaccinex?

Wall Street analysts have given Vaccinex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaccinex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Vaccinex?

Vaccinex saw a increase in short interest in May. As of May 28th, there was short interest totaling 357,000 shares, an increase of 37.2% from the May 13th total of 260,200 shares. Based on an average daily volume of 640,700 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.4% of the shares of the company are short sold.
View Vaccinex's Short Interest

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Vaccinex

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, May, 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.09.
View Vaccinex's earnings history

How has Vaccinex's stock been impacted by COVID-19 (Coronavirus)?

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCNX shares have decreased by 36.0% and is now trading at $2.67.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VCNX?

2 Wall Street analysts have issued 12 month price targets for Vaccinex's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Vaccinex's stock price to reach $7.00 in the next year. This suggests a possible upside of 162.2% from the stock's current price.
View analysts' price targets for Vaccinex
or view top-rated stocks among Wall Street analysts.

Who are Vaccinex's key executives?

Vaccinex's management team includes the following people:
  • Dr. Maurice Zauderer Ph.D., Co-Founder, CEO, Pres & Director (Age 75, Pay $357.26k)
  • Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 47, Pay $231.7k)
  • Dr. Ernest S. Smith Ph.D., Sr. VP of Research & Chief Scientific Officer (Age 50, Pay $249.71k)
  • Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
  • Ms. Elizabeth E. Evans, Chief Operating Officer (Age 49)
  • Mr. John E. Leonard Ph.D., Sr. VP of Devel. (Age 75)

Who are some of Vaccinex's key competitors?

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.23%), Oppenheimer & Co. Inc. (0.15%), UBS Group AG (0.10%), Goldman Sachs Group Inc. (0.07%), Institute for Wealth Management LLC. (0.07%) and Virtu Financial LLC (0.07%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General and Maurice Zauderer.
View institutional ownership trends for Vaccinex

Which institutional investors are selling Vaccinex stock?

VCNX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Oppenheimer & Co. Inc..
View insider buying and selling activity for Vaccinex
or view top insider-selling stocks.

Which institutional investors are buying Vaccinex stock?

VCNX stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, UBS Group AG, Institute for Wealth Management LLC., Virtu Financial LLC, and Bank of New York Mellon Corp. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, Catalyst Group Managem General, and Maurice Zauderer.
View insider buying and selling activity for Vaccinex
or or view top insider-buying stocks.

How do I buy shares of Vaccinex?

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $2.67.

How much money does Vaccinex make?

Vaccinex has a market capitalization of $75.96 million and generates $630,000.00 in revenue each year.

How many employees does Vaccinex have?

Vaccinex employs 39 workers across the globe.

What is Vaccinex's official website?

The official website for Vaccinex is

Where are Vaccinex's headquarters?

Vaccinex is headquartered at 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.